Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.78 |
| ▸ | HPGD | P15428 | 5/20 | 0.78 |
| ▸ | MAOB | P27338 | 4/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | CA12 | O43570 | 2/20 | 0.78 |
| ▸ | CA2 | P00918 | 2/20 | 0.78 |
| ▸ | CA3 | P07451 | 2/20 | 0.78 |
| ▸ | CA6 | P23280 | 2/20 | 0.78 |
| ▸ | CA7 | P43166 | 2/20 | 0.78 |
| ▸ | CA9 | Q16790 | 2/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA5A | P35218 | 1/20 | 0.78 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366230 | 0.89 | ALDH1A1 (0.81) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL52650 | 0.89 | ALDH1A1 (0.81) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL29963204 | 0.88 | KDM4E (1.00) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL1104931 | 0.88 | ALDH1A1 (1.00) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL978456 | 0.88 | KDM4E (1.00) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL2531452 | 0.87 | ALDH1A1 (0.82) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL11829416 | 0.87 | ALDH1A1 (0.76) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL6687148 | 0.87 | MAOB (0.76) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL455614 | 0.87 | ALDH1A1 (0.76) | SLC16A3ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL28373994 | 0.86 | SLC16A3 (0.80) | SLC16A3MAOBCA12CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409871-A | Acrylic acid metal salt resin containing coumarin structure, and preparation method and application thereof | 中国海洋大学 | 2025-02-11 | — | — | CN | claimed |
| US-20240200081-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | Aptacure Therapeutics Limited (CN) | 2024-06-20 | — | — | US | claimed |
| EP-4316495-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | Aptacure Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | claimed |
| CN-117500511-A | Nucleic acid molecule conjugates with extended in vivo half-life | 安沛治疗有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115109021-B | Synthesis of N- (4-alkoxyphenyl) -7-methoxycoumarin-3-carboxamide, gel prepared by same and application thereof | 天津大学 | 2023-09-12 | — | — | CN | claimed |
| CN-115308186-B | fluorescence-pH biosensor and preparation method and application thereof | 广州市乾相生物科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115308186-A | fluorescence-pH biosensor and preparation method and application thereof | 广州市乾相生物科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| WO-2022199685-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | 安沛治疗有限公司 | 2022-09-29 | — | — | WO | claimed |
| CN-115109021-A | Synthesis of N- (4-alkoxy phenyl) -7-methoxy coumarin-3-formamide, gel prepared from N- (4-alkoxy phenyl) -7-methoxy coumarin-3-formamide and application of gel | 天津大学 | 2022-09-27 | — | — | CN | claimed |
| CN-112898278-B | Preparation and application of Sigma-2 fluorescent ligand | 广东医科大学 | 2022-05-13 | — | — | CN | claimed |
| EP-2303908-B1 | FLUORESCENT CYCLIC PEPTIDES, METHODS FOR THE PREPARATION THEREOF, AND USE OF SAID PEPTIDES FOR MEASURING THE ENZYMATIC ACTIVITY OF A PROTEASE ENZYME | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-07-26 | — | — | EP | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100317027-A1 | SULFENIC ACID-REACTIVE COMPOUNDS AND THEIR METHODS OF SYNTHESIS AND USE IN DETECTION OR ISOLATION OF SULFENIC ACID-CONTAINING COMPOUNDS | POOLE LESLIE B | 2010-12-16 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| US-20080070261-A1 | SULFENIC ACID-REACTIVE COMPOUNDS | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2008-03-20 | — | — | US | claimed |
| US-20060084173-A1 | Sulfenic acid-reactive compounds and their methods of synthesis and use in detection or isolation of sulfenic acid-containing compounds | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2006-04-20 | — | — | US | claimed |
| US-4147552-A | Light-sensitive compositions with 3-substituted coumarin compounds as spectral sensitizers | EASTMAN KODAK COMPANY (US) | 1979-04-03 | — | — | US | claimed |
| JP-3109402-A | — | — | None | — | — | JP | disclosed |
| US-4159268-A | ANTIBIOTICS, MICROBIOCIDES | AMERICAN CYANAMID COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070261-A1 | SULFENIC ACID-REACTIVE COMPOUNDS | QSOX1, SQOR, PRDX1 | SLC16A3 3916/4885ALDH1A1 138/4885KDM4E 3725/4885 |
| US-20240200081-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | SOST, FABP1, VEGFA | SLC16A3 130/4885ALDH1A1 892/4885KDM4E 4462/4885 |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | SLC16A3 661/4885ALDH1A1 1901/4885KDM4E 2504/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | SLC16A3 222/4885ALDH1A1 1510/4885KDM4E 1109/4885 |
| US-20100317027-A1 | SULFENIC ACID-REACTIVE COMPOUNDS AND THEIR METHODS OF SYNTHESIS AND USE IN DETECTION OR ISOLATION OF SULFENIC ACID-CONTAINING COMPOUNDS | QSOX1, SQOR, TST | SLC16A3 4077/4885ALDH1A1 323/4885KDM4E 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.